EUVIMEDEUVIMED entdecken
Crossref

Iterative Design of a Prodrug Nanocarrier for Cell Cycle Arrest, Immune Modulation, and Enhanced T Cell Infiltration for Colon Cancer Therapy

Zhenhan Feng iD, Mengmeng Qin, Jinhong Jiang, Meng Wang iD, Tianyu Zhang, Yibo Li, Xiangsheng Liu, Jinfang Zhang, Hubing Shi, Yuliang Zhao iD, Huan Meng iD

Nano Letters · 2025

DOI: 10.1021/acs.nanolett.4c06018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nano Letters, 2025. Verfasst von Zhenhan Feng und 10 weiteren Autor:innen. Beteiligte Einrichtung: CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscien…. Hauptthemen laut MEDLINE: Prodrugs, Colonic Neoplasms, Cell Cycle Checkpoints, T-Lymphocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Chinese Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsColonic NeoplasmsCell Cycle CheckpointsT-LymphocytesNanoparticlesDrug CarriersAntineoplastic AgentsProtein Kinase InhibitorsAnimalsMiceHumansTumor MicroenvironmentLiposomesCell Line, TumorCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6

Stichwörter der Autor:innen

CDK4/6 inhibitorT cell exclusioncell cycle inhibitionimmunogenic cell deathprodrug liposome

Substanzen

ProdrugsLiposomesCyclin-Dependent Kinase 4Drug CarriersCyclin-Dependent Kinase 6Antineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.
  • University of Chinese Academy of Sciences, Beijing 100049, China.
  • Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
  • Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China.
  • Department of Hepatobiliary and Pancreatic Surgery, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Taikang Center for Life and Medical Sciences, Zhongnan Hospital of Wuhan University,…
  • Institute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan 610041, China.

ORCID-Profile: Zhenhan Feng, Meng Wang, Yuliang Zhao, Huan Meng

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Chinese Academy of Sciences

Zitieren

APA

Feng, Z., Qin, M., Jiang, J., Wang, M., Zhang, T., Li, Y., Liu, X., Zhang, J., Shi, H., Zhao, Y., & Meng, H. (2025). Iterative Design of a Prodrug Nanocarrier for Cell Cycle Arrest, Immune Modulation, and Enhanced T Cell Infiltration for Colon Cancer Therapy. Nano Letters. https://doi.org/10.1021/acs.nanolett.4c06018

Vancouver

Feng Z, Qin M, Jiang J, Wang M, Zhang T, Li Y, et al. Iterative Design of a Prodrug Nanocarrier for Cell Cycle Arrest, Immune Modulation, and Enhanced T Cell Infiltration for Colon Cancer Therapy. Nano Letters. 2025. doi:10.1021/acs.nanolett.4c06018

BibTeX
@article{Feng2025,
  author = {Feng, Zhenhan and Qin, Mengmeng and Jiang, Jinhong and Wang, Meng and Zhang, Tianyu and Li, Yibo and Liu, Xiangsheng and Zhang, Jinfang and Shi, Hubing and Zhao, Yuliang and Meng, Huan},
  title = {Iterative Design of a Prodrug Nanocarrier for Cell Cycle Arrest, Immune Modulation, and Enhanced T Cell Infiltration for Colon Cancer Therapy},
  journal = {Nano Letters},
  year = {2025},
  doi = {10.1021/acs.nanolett.4c06018}
}
Kostenlos starten →